MEDTRONIC AVE BRIDGE AURORA BILIARY STENT SYSTEM (AURORA)

K030839 · Medtronic Ave, Inc. · FGE · May 30, 2003 · Gastroenterology, Urology

Device Facts

• Record ID: K030839
• Device Name: MEDTRONIC AVE BRIDGE AURORA BILIARY STENT SYSTEM (AURORA)
• Applicant: Medtronic Ave, Inc.
• Product Code: FGE · Gastroenterology, Urology
• Decision Date: May 30, 2003
• Decision: SESU
• Submission Type: Special
• Regulation: 21 CFR 876.5010
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Aurora Biliary Stent System is indicated for use in the palliation of malignant neoplasms in the biliary tree.

Device Story

The Medtronic AVE Bridge Aurora Biliary Stent System is a self-expanding, tubular nitinol stent pre-loaded on a sheathed delivery catheter. Designed for use in the biliary tree to palliate malignant neoplasms; the device is delivered transhepatically to a stricture site under fluoroscopic guidance using radiopaque markers. Once positioned, the sheath is withdrawn, allowing the stent to self-expand and open the biliary lumen. The device is intended for use by physicians in a clinical setting. It provides a lower crossing profile compared to the predicate device, facilitating easier navigation to the target site. The stent is provided sterile for single use only.

Clinical Evidence

Bench testing only. Preclinical testing was conducted to confirm the safe and effective performance and biocompatibility of the device.

Technological Characteristics

Self-expanding tubular stent constructed of nickel-titanium (nitinol). Features a sheathed delivery catheter with radiopaque markers for fluoroscopic visualization. Provided sterile; single-use. No software or electronic components.

Indications for Use

Indicated for the palliation of malignant neoplasms in the biliary tree.

Regulatory Classification

Identification

A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.

Special Controls

*Classification.* Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.

Predicate Devices

• Bridge Aurora (K030839)

Submission Summary (Full Text)

{0}------------------------------------------------

MAY 3 0 2003

:

K030839

ge _ 1/2

fa

## 510(k) Summary for the Medtronic AVE Bridge Aurora Biliary Stent System

| 510(k)<br>Summary | This summary of 510(k) safety and effectiveness information is being<br>submitted in accordance with the requirements of 21 C.F.R. § 807.92. |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Submitter | Medtronic AVE, Inc.<br>Peripheral Technologies<br>3576 Unocal Place<br>Santa Rosa, California 95407 |
| Contact Person | Marlene Cobb-Carlson<br>Associate Product Regulation Manager<br>Phone: [phone]<br>FAX: [phone]<br>e-mail: [e-mail] |
| Date Prepared | March 14, 2003 |
| Trade Name | Medtronic AVE Bridge™ Aurora™ Self-Expanding Biliary Stent System<br>( |
| Device Description | The subject device is a system consisting of a single-lumen, tubular, self-<br>expanding nickel-titanium ("nitinol") stent pre-loaded onto a sheathed<br>delivery catheter. The stent design and catheter incorporate radiopaque<br>markers to aid in stent placement during fluoroscopy. The delivery<br>system is designed to deliver the stent to the stricture site. Once<br>positioned at the stricture site, the sheath is withdrawn and the stent is<br>released. Upon release, the stent's expansion results in the opening of the<br>constructed lumen within the biliary tree. |
| Indications for Use | The Aurora is indicated for use in the palliation of malignant neoplasm in<br>the biliary tree. |
| Technological<br>Characteristics | The Aurora is substantially equivalent to the currently marketed<br>Bridge Aurora. The subject and predicate stents are technologically<br>similar and are intended for palliation of malignant neoplasms in the<br>biliary tree. The subject and predicate stents are constructed of<br>biocompatible materials. The subject and predicate stents are deployed<br>transhepatically via a sheathed delivery system. The subject device<br>offers a lower crossing profile. The subject and predicate stents are<br>comparable and are intended to meet clinical needs. The difference<br>between the subject and predicate devices are minor and are not<br>relevant to the ability of the subject device to palliate malignant<br>neoplasms in the biliary tree. |
| Nonclinical<br>Performance | Preclinical testing was conducted to confirm the safe and effective<br>performance of this device as well as the biocompatibility of the device. |
| Sterilization | The Aurora is provided sterile. The device is not intended for reuse or<br>resterilization. |
| Conclusion | The Aurora is substantially equivalent to the currently cleared and<br>marketed device and meets the clinical needs of the physicians. |

{1}------------------------------------------------

Page 2/2

## Ko30839

## 510(k) Summary for the Medtronic AVE Bridge Polaris Biliary Stent System

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of a human figure with outstretched arms, resembling a bird in flight. The figure is composed of three curved lines that create the impression of movement and dynamism. Encircling the figure is the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.

.

MAY 3 0 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Marlene Cobb-Carlson Associate Product Regulation Manager Medtronic AVE 3576 Unocal Place SANTA ROSA CA 95403

Re: K030839

Trade/Device Name: Medtronic AVE Bridge Aurora Biliary Stent System Regulation Number: 21 CFR 876.5010 Regulation Name: Biliary catheter and accessories Regulatory Class: II Product Code: 78 FGE Dated: May 1, 2003 Received: May 2, 2002

Dear Ms. Cobb-Carlson:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:

The safety and effectiveness of this device for use in the vascular system have not been established.

Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.

{3}------------------------------------------------

## Page 2 - Ms. Cobb-Carlson

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement above is added to your labeling, as described.

Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.

If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801 and additionally Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification''(21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Daniel G. Schultz, M.

Daniel G. Schultz, M.D. Director Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Page __ 1 of 1

510(k) Number (if known): K030839

Device Name: Medtronic AVE Bridge Aurora Biliary Stent System

FDA's Statement of the Indications For Use for device:

The Aurora Biliary Stent System is indicated for use in the palliation of malignant neoplasms in the biliary tree.

Prescription Use V OR (Per 21 CFR 801.109)

Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________

David A. Liguori

ictive, Abdominal,